Unconventional T Cell Targets for Cancer Immunotherapy
Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with M...
Gespeichert in:
| Veröffentlicht in: | Immunity (Cambridge, Mass.) Mass.), 2018-03, Vol.48 (3), p.453-473 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 473 |
|---|---|
| container_issue | 3 |
| container_start_page | 453 |
| container_title | Immunity (Cambridge, Mass.) |
| container_volume | 48 |
| creator | Godfrey, Dale I. Le Nours, Jérôme Andrews, Daniel M. Uldrich, Adam P. Rossjohn, Jamie |
| description | Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted.
Godfrey et al. review the current understanding of the roles of unconventional T cells in tumor immunity, and discuss the therapeutic potential of harnessing the anti-tumor functions of cells characterized by repeated patterns of TCR usage in unrelated individuals. |
| doi_str_mv | 10.1016/j.immuni.2018.03.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2017055366</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1074761318300852</els_id><sourcerecordid>2017170534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-cab571977d7a003b570c68bd03b22a2115ad4bf26ea759af7f5105608af3ebab3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMorq7-A5GCFy-tk6ZJ2osgxY-FBS-755CmqWbZNmvSLuy_N6WrBw-eZgLPO5N5ELrBkGDA7GGTmLYdOpOkgPMESAJQnKALDAWPM5zD6djzLOYMkxm69H4DgDNawDmapQVlKS7oBWLrTtlur7ve2E5uo1VU6m0o0n3o3keNdVEpO6VdtBi32f5TO7k7XKGzRm69vj7WOVq_PK_Kt3j5_roon5axynLex0pWlOOC85pLABIeoFhe1aFNU5liTGWdVU3KtOS0kA1vKAbKIJcN0ZWsyBzdT3N3zn4N2veiNV6FH8pO28GLcDsHSgljAb37g27s4MJNEzVyJAtUNlHKWe-dbsTOmVa6g8AgRq9iIyavYyoXQETwGmK3x-FD1er6N_QjMgCPE6CDjb3RTnhldBBXG6dVL2pr_t_wDUWfiYs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2017170534</pqid></control><display><type>article</type><title>Unconventional T Cell Targets for Cancer Immunotherapy</title><source>Elsevier ScienceDirect Journals Complete</source><source>Cell Press Free Archives</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Godfrey, Dale I. ; Le Nours, Jérôme ; Andrews, Daniel M. ; Uldrich, Adam P. ; Rossjohn, Jamie</creator><creatorcontrib>Godfrey, Dale I. ; Le Nours, Jérôme ; Andrews, Daniel M. ; Uldrich, Adam P. ; Rossjohn, Jamie</creatorcontrib><description>Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted.
Godfrey et al. review the current understanding of the roles of unconventional T cells in tumor immunity, and discuss the therapeutic potential of harnessing the anti-tumor functions of cells characterized by repeated patterns of TCR usage in unrelated individuals.</description><identifier>ISSN: 1074-7613</identifier><identifier>EISSN: 1097-4180</identifier><identifier>DOI: 10.1016/j.immuni.2018.03.009</identifier><identifier>PMID: 29562195</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antigens ; Cancer ; Cancer immunotherapy ; CD4 antigen ; CD8 antigen ; Histocompatibility antigen HLA ; Immune system ; Immunity ; Immunotherapy ; Ligands ; Lymphocytes ; Lymphocytes T ; Major histocompatibility complex ; Medical prognosis ; Mucosa ; Mutation ; Natural killer cells ; Peptides ; T cell receptors ; Tumors</subject><ispartof>Immunity (Cambridge, Mass.), 2018-03, Vol.48 (3), p.453-473</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Mar 20, 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-cab571977d7a003b570c68bd03b22a2115ad4bf26ea759af7f5105608af3ebab3</citedby><cites>FETCH-LOGICAL-c487t-cab571977d7a003b570c68bd03b22a2115ad4bf26ea759af7f5105608af3ebab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1074761318300852$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29562195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Godfrey, Dale I.</creatorcontrib><creatorcontrib>Le Nours, Jérôme</creatorcontrib><creatorcontrib>Andrews, Daniel M.</creatorcontrib><creatorcontrib>Uldrich, Adam P.</creatorcontrib><creatorcontrib>Rossjohn, Jamie</creatorcontrib><title>Unconventional T Cell Targets for Cancer Immunotherapy</title><title>Immunity (Cambridge, Mass.)</title><addtitle>Immunity</addtitle><description>Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted.
Godfrey et al. review the current understanding of the roles of unconventional T cells in tumor immunity, and discuss the therapeutic potential of harnessing the anti-tumor functions of cells characterized by repeated patterns of TCR usage in unrelated individuals.</description><subject>Antigens</subject><subject>Cancer</subject><subject>Cancer immunotherapy</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Histocompatibility antigen HLA</subject><subject>Immune system</subject><subject>Immunity</subject><subject>Immunotherapy</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Major histocompatibility complex</subject><subject>Medical prognosis</subject><subject>Mucosa</subject><subject>Mutation</subject><subject>Natural killer cells</subject><subject>Peptides</subject><subject>T cell receptors</subject><subject>Tumors</subject><issn>1074-7613</issn><issn>1097-4180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAQhoMorq7-A5GCFy-tk6ZJ2osgxY-FBS-755CmqWbZNmvSLuy_N6WrBw-eZgLPO5N5ELrBkGDA7GGTmLYdOpOkgPMESAJQnKALDAWPM5zD6djzLOYMkxm69H4DgDNawDmapQVlKS7oBWLrTtlur7ve2E5uo1VU6m0o0n3o3keNdVEpO6VdtBi32f5TO7k7XKGzRm69vj7WOVq_PK_Kt3j5_roon5axynLex0pWlOOC85pLABIeoFhe1aFNU5liTGWdVU3KtOS0kA1vKAbKIJcN0ZWsyBzdT3N3zn4N2veiNV6FH8pO28GLcDsHSgljAb37g27s4MJNEzVyJAtUNlHKWe-dbsTOmVa6g8AgRq9iIyavYyoXQETwGmK3x-FD1er6N_QjMgCPE6CDjb3RTnhldBBXG6dVL2pr_t_wDUWfiYs</recordid><startdate>20180320</startdate><enddate>20180320</enddate><creator>Godfrey, Dale I.</creator><creator>Le Nours, Jérôme</creator><creator>Andrews, Daniel M.</creator><creator>Uldrich, Adam P.</creator><creator>Rossjohn, Jamie</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20180320</creationdate><title>Unconventional T Cell Targets for Cancer Immunotherapy</title><author>Godfrey, Dale I. ; Le Nours, Jérôme ; Andrews, Daniel M. ; Uldrich, Adam P. ; Rossjohn, Jamie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-cab571977d7a003b570c68bd03b22a2115ad4bf26ea759af7f5105608af3ebab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Antigens</topic><topic>Cancer</topic><topic>Cancer immunotherapy</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Histocompatibility antigen HLA</topic><topic>Immune system</topic><topic>Immunity</topic><topic>Immunotherapy</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Major histocompatibility complex</topic><topic>Medical prognosis</topic><topic>Mucosa</topic><topic>Mutation</topic><topic>Natural killer cells</topic><topic>Peptides</topic><topic>T cell receptors</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Godfrey, Dale I.</creatorcontrib><creatorcontrib>Le Nours, Jérôme</creatorcontrib><creatorcontrib>Andrews, Daniel M.</creatorcontrib><creatorcontrib>Uldrich, Adam P.</creatorcontrib><creatorcontrib>Rossjohn, Jamie</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Immunity (Cambridge, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Godfrey, Dale I.</au><au>Le Nours, Jérôme</au><au>Andrews, Daniel M.</au><au>Uldrich, Adam P.</au><au>Rossjohn, Jamie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unconventional T Cell Targets for Cancer Immunotherapy</atitle><jtitle>Immunity (Cambridge, Mass.)</jtitle><addtitle>Immunity</addtitle><date>2018-03-20</date><risdate>2018</risdate><volume>48</volume><issue>3</issue><spage>453</spage><epage>473</epage><pages>453-473</pages><issn>1074-7613</issn><eissn>1097-4180</eissn><abstract>Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility complex (MHC) class I and MHC class II molecules, respectively. However, unconventional T cells, which interact with MHC class Ib and MHC-I like molecules, are also implicated in tumor immunity, although their role therein is unclear. These include unconventional T cells targeting MHC class Ib molecules such as HLA-E and its murine ortholog Qa-1b, natural killer T (NKT) cells, mucosal associated invariant T (MAIT) cells, and γδ T cells. Here, we review the current understanding of the roles of these unconventional T cells in tumor immunity and discuss why further studies into the immunotherapeutic potential of these cells is warranted.
Godfrey et al. review the current understanding of the roles of unconventional T cells in tumor immunity, and discuss the therapeutic potential of harnessing the anti-tumor functions of cells characterized by repeated patterns of TCR usage in unrelated individuals.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29562195</pmid><doi>10.1016/j.immuni.2018.03.009</doi><tpages>21</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1074-7613 |
| ispartof | Immunity (Cambridge, Mass.), 2018-03, Vol.48 (3), p.453-473 |
| issn | 1074-7613 1097-4180 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2017055366 |
| source | Elsevier ScienceDirect Journals Complete; Cell Press Free Archives; EZB-FREE-00999 freely available EZB journals |
| subjects | Antigens Cancer Cancer immunotherapy CD4 antigen CD8 antigen Histocompatibility antigen HLA Immune system Immunity Immunotherapy Ligands Lymphocytes Lymphocytes T Major histocompatibility complex Medical prognosis Mucosa Mutation Natural killer cells Peptides T cell receptors Tumors |
| title | Unconventional T Cell Targets for Cancer Immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T12%3A09%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unconventional%20T%20Cell%20Targets%20for%20Cancer%20Immunotherapy&rft.jtitle=Immunity%20(Cambridge,%20Mass.)&rft.au=Godfrey,%20Dale%20I.&rft.date=2018-03-20&rft.volume=48&rft.issue=3&rft.spage=453&rft.epage=473&rft.pages=453-473&rft.issn=1074-7613&rft.eissn=1097-4180&rft_id=info:doi/10.1016/j.immuni.2018.03.009&rft_dat=%3Cproquest_cross%3E2017170534%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2017170534&rft_id=info:pmid/29562195&rft_els_id=S1074761318300852&rfr_iscdi=true |